TerminatedNot Applicable

Effect of Consuming a Bioactive Compound (EPP) on Joint Health in Healthy Adults

Stopped: Loss of the strategic interest because the market potential is insufficient

Spain37 participantsStarted 2022-12-01

Plain-language summary

The objective of this trial is to determine the efficacy of oral administration of a bioactive compound (EPP) in healthy individuals with mild knee joint discomfort.

Who can participate

Age range35 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy participants (men and women) between 35 and 65 years of age with knee discomfort.
✓. Mild knee joint pain (visual analog scale between 3 and 6 cm).

Exclusion criteria

✕. People with clinical osteoarthritis or any other degenerative joint disease.
✕. Persons receiving treatment with anti-inflammatory or chondroprotective drugs (chondroitin sulfate, glucosamine, HA, diacerein) two weeks prior to screening.
✕. Persons receiving intra-articular injections in the knee joint in the 3 months prior to the study.

What they're measuring

KOOS test total score.

Timeframe: 12 weeks

Trial details

NCT IDNCT06650670

SponsorBiosearch S.A.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-08-01

View on ClinicalTrials.gov More Knee Discomfort trials